Trials / Withdrawn
WithdrawnNCT00121017
A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects
A Randomized, Open-Label Study Assessing Safety, Tolerability and Efficacy of an Induction-Maintenance Treatment Strategy Including Lopinavir/Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine Versus Efavirenz Plus Tenofovir Disoproxil Fumarate and Emtricitabine in Antiviral-naïve HIV-1/HCV Co-Infected Subjects
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether a simplified lopinavir/ritonavir-based therapy will continue to keep the viral load at very low levels after initial treatment with a combination of Kaletra (lopinavir/ritonavir) plus tenofovir and emtricitabine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Kaletra (lopinavir/ritonavir) | |
| DRUG | Sustiva (efavirenz) | |
| DRUG | Truvada (emtricitabine/tenofovir disoproxil fumarate) |
Timeline
- First posted
- 2005-07-21
- Last updated
- 2006-07-27
Source: ClinicalTrials.gov record NCT00121017. Inclusion in this directory is not an endorsement.